Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CanSino Biologics's Enterprise Value is €1,287.3 Mil.
CanSino Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €-15.8 Mil. Therefore, CanSino Biologics's EV-to-FCF for today is -81.61.
The historical rank and industry rank for CanSino Biologics's EV-to-FCF or its related term are showing as below:
STU:CJH'
s EV-to-FCF Range Over the Past 10 Years
Min: -183.2 Med: -14.19 Max: 37.66
Current: -44.65
During the past 9 years, the highest EV-to-FCF of CanSino Biologics was 37.66. The lowest was -183.20. And the median was -14.19.
STU:CJH's EV-to-FCF is ranked worse than 100% of 573
companies
in the Drug Manufacturers industry
Industry Median: 19.25
vs STU:CJH: -44.65
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CanSino Biologics's PE Ratio (TTM) for today is calculated as:
CanSino Biologics's share price for today is €3.12.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CanSino Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CanSino Biologics EV-to-FCF Related Terms
CanSino Biologics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for CanSino Biologics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanSino Biologics EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where CanSino Biologics's EV-to-FCF falls into.
CanSino Biologics's current Enterprise Value is €1,287.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CanSino Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €-15.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanSino Biologics (STU:CJH) has a EV-to-FCF of -81.61 as of Sep. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CanSino Biologics and its competitors. According to the industry distribution chart, CanSino Biologics ranks #999999 out of 573 companies in the Drug Manufacturers industry.
Is CanSino Biologics' EV-to-FCF too high?
CanSino Biologics' current EV-to-FCF is -81.61. Based on the distribution chart, CanSino Biologics ranks #999999 out of 573 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, CanSino Biologics has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CanSino Biologics ranks #999999 out of 573 companies for EV-to-FCF. This places CanSino Biologics in the lower half of its industry. The industry median EV-to-FCF is 19.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.25, based on 573 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CanSino Biologics and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanSino Biologics's current EV-to-FCF is -81.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (STU:CJH) is currently considered Significantly Undervalued. The stock's GF Value™ is €6.94, compared to a current price of €3.12 — trading 55% below its estimated fair value. The current EV-to-FCF is -81.61. CanSino Biologics' overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For CanSino Biologics (STU:CJH), the current EV-to-FCF is -81.61 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CanSino Biologics (STU:CJH) Overvalued in 2026?
Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued.
The current stock price of €3.12 is trading 55% below its estimated GF Value™ of €6.94.
GuruFocus considers CanSino Biologics to be Significantly Undervalued.
Key valuation signals for STU:CJH:
EV-to-FCF: -81.61
GF Value™: €6.94 vs. price of €3.12 (55% below fair value)
No single metric tells the full story. See the STU:CJH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CanSino Biologics Inc. is a Chinese biopharmaceutical company that researches, develops, manufactures, and commercializes human vaccines. Its commercial portfolio includes Menhycia and Menphecia for meningococcal disease, the pneumococcal vaccine iPneucia, and Convidecia, an inhaled adenovirus-based COVID-19 vaccine developed with the Beijing Institute of Biotechnology. The company also markets Ad5-EBOV for Ebola. Its pipeline spans preventive vaccines against tetanus, diphtheria, pertussis, poliomyelitis, pneumococcal disease, tuberculosis, and shingles, along with earlier-stage candidates targeting influenza and other infectious diseases. CanSino sells primarily to public health authorities and vaccination programs in China, which accounts for the large majority of its revenue, and it has pursued international distribution and licensing agreements in emerging markets. Revenue comes from vaccine sales and, to a lesser extent, collaboration and licensing arrangements with partners. The company is headquartered in Tianjin and listed in Hong Kong and Shanghai.
68GF Score
Get the complete analysis for STU:CJH
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CJH has been successfully added to your 
